A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients

Antiviral Therapy

Volumn 10, Issue 6, 2005, Pages 761-767

  Ananworanich, Jintanat ^a   Hill, Andrew ^b   Siangphoe, Umaporn ^a   Ruxrungtham, Kiat ^a,c   Prasithsirikul, Wisit ^d   Chetchotisakd, Ploenchan ^e   Kiertiburanakul, Sasisopin ^f   Munsakul, Warangkana ^g   Raksakulkarn, Phitsanu ^h   Tansuphasawadikul, Somboon ⁱ   Nuesch, Reto ^j   Cooper, David A ^k   Hirschel, Bernard ^l  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Bamrasnaradura Infectious Disease Institute   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^h Sanpatong Hospital   (Thailand)

ⁱ Buddhachinnaraj Hospital   (Thailand)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; VOMITING; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; THAILAND; TREATMENT OUTCOME;

EID: 25444499748     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S & Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
2. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I & Youle M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2003; 4(Suppl 1):1-41.
3. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2003 Revision. 2004. Geneva, World Health Organization.
4. Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA & Phanuphak P. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes 2003; 32:375-379.
5. Kurowski M, Sternfeld T, Sawyer A, Hill A & Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine 2003; 4:94-100.
6. Hijazi Y, Riek M, Gaudeul-Erhart E & Grange S. Saquinavir 500mg tablet, a new formulation, has similar bioavailability to invirase 200mg capsule for healthy volunteers at 1000/100mg BID dosing with ritonavir. 2nd IAS Conference on HIV Pathogenesis and Treatment. 12-16 July 2003, Paris, France. Abstract 534.
7. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z & Lundgren JD. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. The Journal of Infectious Diseases 2003; 188:635-642.
8. Youle M, Gerstoft J, Fox Z, Losso M, Jayaweera D, Rieger A, Bruun JN, Castagna A, Walmsley S, Hill A, Dragsted UB, Lundgren JD, for the MaxCmin2 trial group. The final 48 week analysis of a phase IV, randomised, open-label, multicenter trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100mg BID) versus saquinavir/ritonavir (1000/100 mg BID): the MaxCmin2 trial. 9th European AIDS Conference. 25-29 October 2003, Warsaw, Poland. Abstract F11/3.
9. Montaner JS, Saag MS, Barylski C & Siemon-Hryczyk P. Focus Study: Saquinavir QD regimen versus efavirenz QD regimen week 48 analysis in HIV-infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Abstract H-167.
10. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K & Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. The Journal of Antimicrobial Chemotherapy 2004; 54:785-790.
11. Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM & Phanuphak P. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. Journal of Acquired Immune Deficiency Syndromes 2002; 29:464-470.
12. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N & Saag MS. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. The Journal of Antimicrobial Chemotherapy 2000; 44:2672-2678.
13. Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B & Pozniak A. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antiviral Therapy 2004; 9:423-429.
14. Gieschke R, Fotteler B, Buss N & Steimer JL. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clinical Pharmacokinetics 1999; 37:75-86.
15. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B & Pozniak A. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2004; 48:2388-2393.
16. Ananworanich J, Siangphoe U, Mahanontharit A, Hill A, Hirschel B & Ruxrungtham K. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antiviral Therapy 2004; 9:1035-1036.
17. Zong J, Chittick G, Blum MR, Hill D, Begley J, Adda N, Shah J & Kearney BP. Pharmacokinetic assessment of tenofovir DF (TDF) and ritonavir (RTV)-boosted saquinavir (SQV/r) in healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October-2 November 2004, Washington, DC, USA. Abstract A444.
18. Boffito M, D'Aviolo A, Di Perri G, Sciandra M, Bonara S, Back D, Hill A, Moyle G, Nelson M, Higgs C, Tomkins J, Gazzard B & Pozniak A. Repeated pharmacokinetics of tenofovir disoproxil fumarate (TDF) in HIV-infected adults receiving saquinavir (SQV) hard gel/ritonavir (RTV) 1000/100 mg BID. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 4.19.
19. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ & Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
20. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW & Rousseau F. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292:180-189.
21. Gathe JC Jr, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, Gladysz A, Garris C & Yeo J. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Aids 2004; 18:1529-1537.
22. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. The New England Journal of Medicine 2002; 346:2039-2046.
23. Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA & Phanuphak P. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 2001; 27:116-123.
24. Bartlett JA, DeMasi R, Quinn J, Moxham C & Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. Aids 2001; 15:1369-1377.
25. Schutz M, Goodly J, Chen K & Montaner J. Lack of correlation between saquinavir trough levels and adverse events or clinical outcome in saquinavir cohort of the FOCUS study. 41st Annual meeting, Infectious Diseases Society of America. 9-12 October 2003, San Diego, CA, USA. Abstract 654.
26. Justesen U, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Duran A, Peters B, Obel N, Castagna A, Dragsted U, Lundgren J, on behalf of the MaxCmin1 trial group. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg. The MaxCmin1 trial - PK substudy. 9th European AIDS Conference. 25-29 October 2003, Warsaw, Poland. Abstract F2/5.
27. van Heeswijk RP, Cohen Stuart JW, Burger DM, Beijnen JH, Borleffs JC & Hoetelmans RM. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. British Journal of Clinical Pharmacology 2002; 53:211-212.
28. Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH & Hoetelmans RM. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes 2001; 27:344-349.
29. Yeh V, Barros CP & Easterbrook P. Virologic response to a once daily lopinavir/ritonavir (LPV/r) based regimen in ARV-naive patients is not associated with trough lopinavir concentrations or baseline HIV RNA and CD4 count. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October-2 November 2004, Washington, DC, USA. Abstract H-570-363.